Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial

The Lancet

Volumn 384, Issue 9944, 2014, Pages 665-673

  Garon, Edward B ^a   Ciuleanu, Tudor Eliade ^b   Arrieta, Oscar ^c   Prabhash, Kumar ^d   Syrigos, Konstantinos N ^e   Goksel, Tuncay ^f   Park, Keunchil ^g   Gorbunova, Vera ^h   Kowalyszyn, Ruben Dario ⁱ   Pikiel, Joanna ^j   Czyzewicz, Grzegorz ^k   Orlov, Sergey V ^l   Lewanski, Conrad R ^m   Thomas, Michael ⁿ   Bidoli, Paolo ^o   Dakhil, Shaker ^p   Gans, Steven ^q   Kim, Joo Hang ^r   Grigorescu, Alexandru ^s   Karaseva, Nina ^t   Reck, Martin ^u   Cappuzzo, Federico ^v   Alexandris, Ekaterine ^w   Sashegyi, Andreas ^x   Yurasov, Sergey ^w   Pérol, Maurice ^y   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d TATA MEMORIAL HOSPITAL   (India)

^e SOTIRIA GENERAL HOSPITAL   (Greece)

^f EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁱ Centro de Investigaciones Clínicas   (Argentina)

^j Wojewódzkie Centrum Onkologii ^*  (Poland)

^k Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^l PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^m CHARING CROSS HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^o SAN GERARDO HOSPITAL   (Italy)

^p Cancer Center of Kansas   (United States)

^q ST JANSDAL HOSPITAL   (Netherlands)

^r Yonsei University College of Medicine   (South Korea)

^s Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^t City Clinical Oncology Dispensary   (Russian Federation)

^u GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^v ISTITUTO TOSCANO TUMORI   (Italy)

^w ImClone Systems   (United States)

^x ELI LILLY AND COMPANY   (United States)

^y CENTRE LÉON BÉRARD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOCETAXEL; PLACEBO; PLATINUM; RAMUCIRUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEMOPTYSIS; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; INSOMNIA; INTERACTIVE VOICE RESPONSE SYSTEM; KIDNEY FAILURE; LACRIMATION DISORDER; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ARTERIAL THROMBOEMBOLISM; CANCER GROWTH; CANCER SURVIVAL; DRUG FEVER; GENDER; GEOGRAPHY; LACRIMATION; NON SMALL CELL LUNG CANCER; PATIENT HISTORY OF CHEMOTHERAPY; SIDE EFFECT; SMOKING; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLACEBOS; PLATINUM; QUALITY OF LIFE; SURVIVAL RATE; TAXOIDS;

EID: 84906903314     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60845-X     Document Type: Article

References (34)

1. R Siegel, D Naishadham, A Jemal Cancer statistics 2012 CA Cancer J Clin 62 2012 10 29
2. T Li, H-J Kung, PC Mack, DR Gandara Genotyping and genomic profiling of non-small cell-lung cancer: implications for current and future therapies J Clin Oncol 31 2013 1039 1049
3. NB Leighl Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line Curr Oncol 19 2012 S52 S58
4. DE Gerber, JH Schiller Maintenance chemotherapy for advanced non-small cell lung cancer: new life for an old idea J Clin Oncol 31 2013 1009 1020
5. TE Stinchcombe, MA Socinski Current treatments for advanced stage non-small cell lung cancer Proc Am Thorac Soc 6 2009 233 241
6. FA Shepherd, J Dancey, R Ramlau et al. A prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
7. FA Shepherd, JR Pereira, T Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
8. N Hanna, FA Shepherd, FV Fossella et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
9. K Hotta, H Katsuyuki, F Yoshiro et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials J Thorac Oncol 2 2007 402 407
10. M Reck, R Kaiser, A Mellemgaard et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised trial Lancet Oncol 15 2014 143 155
11. D Hanahan, RA Weinberg The hallmarks of cancer Cell 100 2000 57 70
12. M Skobe, P Rockwell, N Goldstein et al. Halting angiogenesis suppresses carcinoma cell invasion Nat Med 3 1997 1222 1227
13. A Sandler, R Gray, MC Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
14. M Reck, J von Pawel, P Zatloukal et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
15. JL Spratlin, RB Cohen, M Eadens et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 2010 780 787
16. CS Fuchs, J Tomasek, CJ Yong et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Lancet 383 2014 31 39
17. H Wilke, E Van Cutsem, S Cheul et al. RAINBOW: a global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy IMCL CP12-0922 (I4T-IE-JVBE) J Clin Oncol 32 suppl 3 2014 abstr LBA7.
18. EB Garon, D Cao, E Alexandris, WJ John, S Yurasov A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design Clin Lung Cancer 13 2012 505 509
19. P Therasse, SG Arbuck, EA Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
20. US Department of Health and Human Services Common Terminology Criteria for Adverse Events v4.0 (CTCAE), 5/2009 update http://evs.nci.nih.gov/ftp1/ CTCAE/Archive/CTCAE-4.02-2009-09-15-QuickReference-8.5x11.pdf (accessed May 19, 2014).
21. PJ Hollen, RJ Gralla, MG Kris, LM Potanovich Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS) Eur J Cancer 29 1993 S51 S58
22. EuroQoL Group EuroQol - a new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
23. CM Booth, EA Eisenhauer Progression-free survival: meaningful or simply measurable? J Clin Oncol 30 2012 1030 1033
24. MC Garassino, O Martelli, M Broggini et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Lancet Oncol 14 2013 981 988
25. FV Fossella, R DeVore, RN Kerr et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens J Clin Oncol 18 2000 2354 2362
26. ES Kim, V Hirsh, T Mok et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
27. M Di Maio, N Lama, A Morabito et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials Eur J Cancer 46 2010 735 743
28. SS Ramalingam, SE Dahlberg, CJ Langer et al. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599 J Clin Oncol 26 2008 60 65
29. Mackey J, Ramos M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. San Antonio Breast Cancer Symposium 36th Annual Meeting; San Antonio, TX, USA; Dec 10-14, 2013: abstr 238.
30. DH Johnson, L Fehrenbacher, WF Novotny et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
31. AB Sandler, JH Schiller, R Gray et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab J Clin Oncol 27 2009 1405 1412
32. JD Hainsworth, L Fang, JE Huang et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer J Thorac Oncol 6 2011 109 114
33. NR Smith, D Baker, NH James et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers Clin Cancer Res 16 2010 3548 3561
34. L Crinò, G Metro Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Eur Respir Rev 23 2014 79 91